Login to Your Account

In The Clinic NEWS

Roche AG is planning early 2016 regulatory filings to seek approvals for ocrelizumab, a twice-yearly injectable MS therapy, after two phase III studies showed that it significantly reduced relapses and disability progression vs. Rebif for people with relapsing MS.

With a progressive strategy that's "building an ecosystem," Biondvax Pharmaceuticals Ltd. offered upbeat preliminary results from the BVX-006 phase II trial gauging the worth of M-001 in the firm's quest for a universal influenza vaccine.

As a paper last month in Nature predicted a "bumpy road" ahead for RNA polymerase II research, pointing to an "additional level of complexity" that has turned up in the work, Pharmamar SA – bolstered by impressive phase II results – forged ahead with the phase III experiment testing PM1183.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: